SURVEY: Gastrointestinal (GI) Testing in Drug Development


The Safety Pharmacology Society (SPS) invites you to participate in their survey titled “Gastrointestinal (GI) Testing in Drug Development.” This survey is a follow-up to the 2018 SPS-FDA GI Workshop and SPS Annual Meeting Track Session “Safety Pharmacology / FDA Discussion on the Gastrointestinal System” and will help support the initiatives of the SPS Regulatory Working Group.

The primary goal of the current survey is to investigate current industry practices employed by the safety pharmacology community for the design, oversight, and impact of in vivo and in vitro studies that evaluate GI safety. The survey contains 32 questions and should take approximately 20 minutes to complete.

To ensure a robust dataset for the survey it is preferred that all questions are answered; respondents are encouraged to reach out to fellow colleagues within their respective organizations if you are not sure how to answer specific questions.

Thank you in advance for your participation and we look forward to sharing the results with the SPS membership as a scientific meeting poster presentation and manuscript.

Follow this link to access the survey. The survey deadline is May 21.


Safety Pharmacology Society Headquarters

Recent Stories
Congratulations 2021 Incoming Board Members!

SPS Announces 2020 Publication Award Recipients

Webinar of Interest! Exploring safety issues in antimicrobial drug development